Sun Pharma agreed to buy Merck’s spinoff Organon in an all-cash transaction valued at $11.75 billion, aiming to expand its presence in women’s health and biosimilars. The deal is structured to move Sun into the top tier of the women’s health market, leveraging Organon’s portfolio and commercial footprint. Sun also framed the acquisition as portfolio expansion rather than a narrow franchise addition, with implications for pipeline continuity and lifecycle management across hormonal, dermatology, and reproductive health categories. The transaction highlights how multinational pharma is repositioning toward specialized therapeutic areas where brand loyalty, adherence, and differentiated product development can support long-cycle value creation.